

8th ERN EURO-NMD **Annual Meeting**

Sleep in Neuromuscular Disorders

5th – 7th March 2025

Matthias Boentert, MD

Department of Sleep Medicine, Neuromedical Centre,

Klinikum Osnabrück, Germany

University of Münster, Münster, Germany



European eference etwork

for rare or low prevalence complex diseases

Network

Neuromuscular Diseases (ERN EURO-NMD)




DOI

Speaker honoraria: Amicus, Sanofi, Biogen, ITF

Advisory boards: Amicus, Sanofi



Troublemakers: Sleep disruptors in NMD



Muscle cramps & fasciculations


Spasticity

Pain

Paresthesia

Sleep apnea

Sleep disturbances in NMD



Boentert, M et al. Clin. Transl. Neurosci. 2023.

- (1) Mitochondriopathies
- (2) Myotonic dystrophies
- (3) Sensory and sensorimotor neuropathies
- (4) Amyotrophic lateral sclerosis, primary lateral sclerosis, and hereditary spastic paraplegia.

Muscle cramps

- Common in the general population
- Very frequent in NMD
- Lower motor neuron sign
- Legs > arms
- Neurogenic > myogenic
- Worsened by diabetes, electrolyte imbalances, dehydration, alcohol, thyroid disease
- Worsened by diuretics, sympathomimetics, statins **Treatment:**
- Avoid triggers & causes
- Try stretching of affected muscle groups
- Try oral Mg or Ca
- Try quinine, but carefully
- Few trials only, e. g. mexiletine in ALS

- Naylor JR, Young JB. Age Ageing. 1994 Sep;23(5):418–20.
- Daniell HW et al. JAMA Intern Med. 2013 May 27;173(10):934–5.
- Blyton F et al. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008496.
- 5. Weiss MD et al. Neurology. 2016;86:1474–81.

NB: Cramps are different from spasticity!

American Academy of Sleep Medicine. International Classification of Sleep Disorders 3rd ed (ICSD-3) 2014.

Spasticity

- Upper motor neuron sign
- Legs > arms (mostly)
- Triggered by movements & spontaneous

Treatment:

- Systemic: baclofen, tizanidine, diazepam, tolperisone, cannabinoids
- Focal: botulinum toxin

- 1. Kerstens, H.C.J.W. et al. Orphanet J. Rare Dis. 2021
- 2. Chou, R. et al. J. Pain Symptom Manag. 2004
- 3. Lapeyre, E. et al. NeuroRehabilitation 2010



Pain

- Extremely common & important
- Majority of patients with FSHD, inflammatory myopathies, ALS
- Never underestimate
- Nociceptive, neuropathic or by central sensitization
- Spontaneous or related to immobilization

Treatment:

- Provide alleviation where and as needed (bed comfort, positioning, medical aids)
- Pharmacotherapy according to presumed origin, symptom burden, and time course of pain
- Follow guidelines for treatment of pain
- Monitor closely
- Beware medication effects on sleep-related breathing



^{1.} Hurwitz, N. et al. Amyotroph. Lateral Scler. Front. Degener. 2021

^{2.} Abresch, R.T. et al. Am. J. Hosp. Palliat. Care 2002

Restless legs

- May be caused, unmasked or aggravated by immobilization
- Distinguish from cramps, paraesthesias, neuropathic pain, or venous stasis
- Strictly follow ICSD-3 diagnostic criteria
- Common in ALS, hereditary and other neuropathies

Treatment:

- Serum ferritin > 75 μg/ml
- Dopaminergics, gabapentin/pregabaline, or oxycodon/naloxone according to current guidelines

American Academy of Sleep Medicine. International Classification of Sleep Disorders 3rd ed (ICSD-3) 2014

- Boentert, M.; et a. J. Neurol. Neurosurg. Psychiatry 2014
- Gemignani, F. et al. Neurology 1999
- Hattan, E. et al. Neurology 2009
- Winkelman, J.W. et al. Neurology 2016

Swallowing – Secretions – Saliva


- Dysphagia common in ALS, OPMD, DMD, SBMA etc.
- Pseudohypersalivation and drooling
- Aspiration risk
- Lower respiratory tract infections •

Treatment

- Speech therapy (logopedics)
- Dextromethorphan/Chinidine (off-label)
- Anticholinergic compounds (as and when needed)
- Botulinum toxin injection or radiation of salivary glands
- Cough assistance



Sleep-disordered breathing





Obstructive sleep apnea

 \rightarrow Intermittent upper airway collapse **Central sleep apnea**

 \rightarrow Intermittent absence of respiratory drive


Symptoms: Sleep disturbances, non-restorative sleep, daytime sleepiness, fatigue



Sleep-related hypoventilation

 \rightarrow Reduced tidal volume and minute ventilation

Upper airway in NMD



Osman AM et al., Nature and Science of Sleep 2018




Disturbance of central respiratory drive (increased loop gain)

Sequelae of NMD: Pharyngeal weakness & hypotonia Impairment of pre-inspiratory pharyngeal tonization Macroglossia (DMD, Pompe)

Obstructive sleep apnea (OSA)

Pathophysiology



- \rightarrow Sleep disruption
- \rightarrow Increases cardiovascular risk and mortality if apnea hypopnea index > 15/h


Prevalence in NMD

Condition	Prevalence of OSA	Reference
CMT	38%	Boentert et al. 2014
ALS	46%	Boentert et al. 2018
DM1	41-60%	Bianchi et al. 2013 Pincherle et al. 2012 Spiesshoefer et al. 2019
FSHD	55%	Runte et al. 2019
DMD	16-31%	Polat et al. 2012

 \rightarrow OSA risk independent of other risk factors


 \rightarrow Beware concomitant hypoventilation!

Gold standard for treatment




\rightarrow Continous positive airway pressure \rightarrow Prevents upper airway collapse \rightarrow Only if hypoventilation is ruled out!

Immediate effects of CPAP



Male patient with CMT1A, 38 yo, BMI 26

Central sleep apnea (CSA)




Female patient with DM1, 37 yo, BMI 24

- \rightarrow Intermittent lack of central respiratory drive
- \rightarrow In people with myotonic dystrophy
- \rightarrow Related to cerebral white matter lesions
- \rightarrow Coincident with OSA and/or sleep-related hypoventilation

\rightarrow Treatment:

Bilevel positive airway pressure with backup rate = non-invasive ventilation



NMD with respiratory muscle weakness

Amyotrophic Lateral Sclerosis	
Spinal Muscular Atrophy I-III	
 Hereditary Neuropathies 	
 Guillain-Barré syndrome 	
 Phrenic nerve palsies 	


Critical-illness neuromyopathy / ICU acquired weakness

MYOGENIC	 Muscular dystrophies 	
	 Limb girdle muscular dystrophi 	
	 Myotonic dystrophy type I 	
	Pompe disease	
	 Congenital myopathies 	

• Myasthenic syndromes


(ALS)

ies




The ERN EURO-NMD is funded by the European Commission under the EU4Health programme (EURO-NMD 23-27 — 101156434 — EU4H-2023-ERN2-IBA)

Capnography superior to oxymetry



Georges M et al., Respirology 2016 Boentert M et al., JNNP 2018



Sensitivity of oxymetry to detect hypoventlation is only 0,69 in people with NMD and chest wall disease.

Overnight capnography is indispensable for early diagnosis of nocturnal hypoventilation.

Diagnostic pathway

ameter	Pros	Cons	Remarks
ep disruption time sleepiness pnea		Non-specific or may not be present	Obligatory
adoxical breathing	Easy to test	None	Test if possible
		. ,	Standard; monitor regularly
positional drop	Better than upright FVC only		If >20%, nocturnal hypoventilation likely
(max. insp. pressure)	Bedside test	Special device needed	-
P (sniff nasal pressure)	Bedside test; MIP surrogate	Special device needed	If mouth closure is weak
o ₂ e excess	Relatively easy to obtain		Daytime hypercapnia late; BE > 2 mmol/l predicts nocturnal hypoventilation
se oxymetry	Widely available	SpO ₂ too insensitive	Insufficient
/graphy	Widely available	SpO ₂ too insensitive	Insufficient w/o capno
/somnography	Sleep staging possible	SpO ₂ too insensitive; costs	Insufficient w/o capno
nography	Highly sensitive	No standard in sleep labs; costs	
	p disruption time sleepiness onea doxical breathing positional drop (max. insp. pressure) (sniff nasal pressure) (sniff nasal pressure) e excess e excess	p disruption time sleepiness oneaPatients tell and showdoxical breathingEasy to testdoxical breathingEasy to testbedside testBedside testpositional dropBetter than upright FVC only(max. insp. pressure)Bedside testo (sniff nasal pressure)Bedside test; MIP surrogatee excessRelatively easy to obtaine oxymetryWidely availablegraphyWidely availablesomnographySleep staging possible	p disruption time sleepiness oneaPatients tell and showNon-specific or may not be presentdoxical breathingEasy to testNoneBedside testGlobal measure of lung function; sensitivity rather lowpositional dropBetter than upright FVC onlyNone(max. insp. pressure)Bedside test; MIP surrogateSpecial device needed2 excessRelatively easy to obtain widely availableNo standard for outpatientse oxymetryWidely availableSpO2 too insensitive spo2 too insensitive spo2 too insensitive; costs


Non-invasive ventilation (NIV): Indication criteria

	NICE 2016	ERS 2002	DGP 2025	ACCP 2023
Clinical	"symptoms"	"symptoms"	Signs and symptoms of respiratory muscle weakness or sleep-disordered breathing	Fatigue, dyspnea, (morning) headache, witnessed apneas
Daytime	 FVC<50 % w/o symptoms FVC <80% w/ symptoms MIP <60 cm H₂O 	 FVC< 80% SNIP <40 cmH2O morning p_aCO₂>45 mm Hg 	 FVC<70% FVC decline >10% within <3 months MIP<60 cm H₂O daytime pCO₂>45 mmHg 	 FVC<50 % w/o symptoms FVC <80% w/ symptoms; MIP/SNIP <60 cmH₂O MEP < 40 cmH₂O pCO₂≥45 mmHg
Nocturnal	-	-	$p_{tc}CO_2 > 50 mmHg$ $\Delta p_{tc}CO_2 \ge 10 mmHg$	$SpO_2 \le 90\%$ for $\ge 2\%$ of sleep time AHI $\ge 5 /h$

\rightarrow consensus needed that better includes overnight capnography

- 1. https://www.nice.org.uk/guidance/qs126/chapter/quality-statement-2-respiratory-assessment-and-noninvasive-ventilation
- 2. Shneerson JM, Simonds AK. Eur Resp J, 2002 20(2): 480-487
- 3. Stanzel SB et al., S3 Guideline: Treating Chronic Respiratory Failure with Non-invasive Ventilation, Pneumologie 2025;79(1):25-79.
- 4. Khan A et al. CHEST, 164, Issue 2, 394 413

Immediate effects of NIV



 \rightarrow Improvement of ventilation, alveolar gas exchange, apnea-hypopnea index, oxygenation, and sleep architecture

 \rightarrow Improvement of sleep quality


NIV: Long-term effects

1 Sleep quality, daytime performance, ability to participate, quality of life

 \Downarrow Work of breathing, energy consumption, weight loss

U Complications and secondary diseases

1 Overall prognosis and survival time




 \rightarrow NIV prolongs life span

 \rightarrow Early NIV is meaningful

Sancho J et al. (2018), ERJ Open Res; Vitacca M et al. (2018), Eur J Neurol; Jimenez JV et al. (2023), Resp Care

→ Normocapnia counts



Grassano M, Ann Neurol 2024;00:1–6

Reginault T et al. Journal of Neurology 2024; 271:5590–5597

The ERN EURO-NMD is funded by the European Commission under the EU4Health programme (EURO-NMD 23-27 — 101156434 — EU4H-2023-ERN2-IBA)

Weakness of cough

Causes

- Severe inspiratory muscle weakness
- Expiratory muscle weakness •
- Weakness of glottic closure



Peak Flow Meter (Peak Cough Flow)

Treatment

- \rightarrow normal/keep monitoring • PCF > 350 l/min
- PCF 270-350 l/min \rightarrow closer monitoring
- PCF 160-270 l/min without mucus retention
 - \rightarrow manually assisted coughing/air stacking
- PCF < 160 l/min or 160-270 l/min with mucus retention
 - \rightarrow mechanical insufflator-exsufflator
 - \rightarrow secretolytic measures if needed

Wrap-up: In NMD...

- ... sleep disturbances are common & meaningful
- ... multifaceted & multifactorial
- ... immobility alone may take its toll
- ... pain, cramps, spasticity and RLS may play a role
- ... obstructive sleep apnea is very common
- ... central sleep apnea occurs in DM1 and mitochondrial disease
- ... respiratory failure starts with sleep-related hypoventilation
- ... capnography beats oximetry
- ... CPAP is for isolated OSA, NIV for CSA and hypoventilation
- ... NIV benefits depend on timing & adherence
- ... beware cough assistance & management of secretions



Thank you for your attention!

matthias.boentert@klinikum-os.de mboenter@uni-muenster.de